Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals develops small molecule therapeutics with novel mechanisms of action for the treatment of severe life-threatening diseases with no approved or effective therapy. Lead investigational molecules, bardoxolone methyl and omaveloxolone, are Nrf2 activators that take advantage of new insights into how genes involved in cellular metabolism and mitochondrial function play a primary role in switching the cellular inflammatory response on and off. Bardoxolone methyl is currently in a pivotal Phase 2/3 (CARDINAL) study for the treatment of chronic kidney disease caused by Alport syndrome, a Phase 3 (FALCON) study for the treatment of ADPKD, and a Phase 3 (CATALYST) study for the treatment of CTD-PAH.